# Progress Note 07 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ernest Hemingway (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET003-SYN-TD
- Date: 1955-08-31
- Fictional facility: St. Posthumous Health Center
- Fictional author: Walter Brandt-Ochoa, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Six-month review: iron, liver, mood, memory and blood pressure. **S**

## History of present illness

Mr. Hemingway returns six months after intake. He has had twenty-two phlebotomies, and the twenty-third is planned after today's blood tests. He has had no alcohol for about fifteen weeks and still takes naltrexone. His mood is steady; the monthly PHQ-9 with the behavioral health clinician was 6 at his preventive visit and is 5 today. He writes every morning and says names and words come to him more easily. Headaches are about once a week. On amlodipine 10 mg his home average is 124/76, with slight ankle swelling in the evenings. The echocardiogram was done this morning. His guns remain at the club; he would like to bring them home before the autumn shooting season, and this was discussed. **S**

| Element | Detail |
|---|---|
| Phlebotomy | Twenty-two sessions; the twenty-third today |
| Alcohol | None for about fifteen weeks; AUDIT-C 0 |
| Mood | PHQ-9 5; item 9 scored 0 |
| Home blood pressure | Average 124/76 on amlodipine 10 mg |
| Cognition | MoCA 27, from 25 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | More energy; weight down 5 kg since intake |
| Cardiovascular | Positive | Slight ankle swelling in the evenings; no chest pain or breathlessness |
| Neurological | Positive | Headaches about once a week; memory better |
| Psychiatric | Negative | Mood steady; no thoughts of suicide or wishes to be dead since the last visit |

4 systems reviewed. **S**

## Current medications

- Naltrexone 50 mg oral tablet, one tablet daily, to reduce heavy drinking **S**
- Sertraline 100 mg oral tablet, one tablet daily **S**
- Amlodipine 10 mg oral tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 126/78 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 92.8 kg; BMI 27.7 kg/m². All vital signs are synthetic.

Hemoglobin: 13.4 g/dL (low); MCV: 93 fL; Platelets: 226 10*3/uL; AST: 27 U/L; ALT: 31 U/L; GGT: 41 U/L; Serum iron: 148 ug/dL; Transferrin saturation: 44%; Ferritin: 268 ng/mL; Total cholesterol: 194 mg/dL; LDL cholesterol: 114 mg/dL; HDL cholesterol: 49 mg/dL; Triglycerides: 136 mg/dL; HbA1c: 5.9% (high); PHQ-9: 5; AUDIT-C: 0; MoCA: 27. All results are synthetic.

## Change since baseline

- Hemoglobin: 15.6 g/dL at baseline, 13.4 g/dL (low) at this visit **S**
- MCV: 102 fL (high) at baseline, 93 fL at this visit **S**
- Platelets: 208 10*3/uL at baseline, 226 10*3/uL at this visit **S**
- AST: 70 U/L (high) at baseline, 27 U/L at this visit **S**
- ALT: 78 U/L (high) at baseline, 31 U/L at this visit **S**
- GGT: 196 U/L (high) at baseline, 41 U/L at this visit **S**
- Serum iron: 214 ug/dL (high) at baseline, 148 ug/dL at this visit **S**
- Transferrin saturation: 76% (high) at baseline, 44% at this visit **S**
- Ferritin: 1460 ng/mL (high) at baseline, 268 ng/mL at this visit **S**
- Total cholesterol: 214 mg/dL (high) at baseline, 194 mg/dL at this visit **S**
- LDL cholesterol: 118 mg/dL at baseline, 114 mg/dL at this visit **S**
- HDL cholesterol: 52 mg/dL at baseline, 49 mg/dL at this visit **S**
- Triglycerides: 236 mg/dL (high) at baseline, 136 mg/dL at this visit **S**
- HbA1c: 6.1% (high) at baseline, 5.9% (high) at this visit **S**
- PHQ-9: 16 at baseline, 5 at this visit **S**
- MoCA: 25 at baseline, 27 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 126/78, pulse 72; weight 92.8 kg |
| Cardiovascular | Regular rhythm; no murmur; trace ankle edema |
| Abdomen | Liver not palpable; no spleen felt |
| Neurological | No tremor; gait normal |
| Psychiatric | Bright, humorous and engaged |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Hereditary hemochromatosis on weekly phlebotomy** (E83.110). Ferritin 268 ng/mL and transferrin saturation 44% after twenty-two sessions; hemoglobin 13.4 g/dL. Echocardiogram shows no iron-related cardiomyopathy. About two more months of weekly sessions should reach a ferritin of 50 to 100 ng/mL. **S**
   - Continue weekly phlebotomy; ferritin every four sessions as the target nears.
   - Then maintenance phlebotomy about every two to four months to keep ferritin 50 to 100 ng/mL.
   - Liver stiffness to be rechecked after iron removal.
2. **Alcohol use disorder, severe, in early remission** (F10.20). About fifteen weeks without alcohol; liver tests and MCV are normal. **S**
   - Continue naltrexone 50 mg daily for at least another six months.
   - Stop thiamine.
3. **Depression on sertraline** (F32.1). PHQ-9 5 from 16: a response, close to remission. Safety reviewed: no thoughts of suicide or wishes to be dead. He asked to bring his guns home for the shooting season; after discussion he chose to keep them at the club until he has been well for a few more months, and to store them locked and unloaded with the ammunition separate when they come home. The 988 Suicide & Crisis Lifeline remains in his phone. **S**
   - Continue sertraline 100 mg for at least six to twelve months after remission.
   - Psychotherapy every two weeks.
   - Firearm storage reviewed again at the next visit.
4. **Hypertension** (I10). At target on amlodipine 10 mg; trace ankle edema, which he does not mind. Echocardiogram shows mild concentric left ventricular hypertrophy with normal function. **S**
   - Continue amlodipine 10 mg daily.
   - Kidney function, potassium and urine albumin at the yearly review.
5. **Post-concussion symptoms** (F07.81). MoCA 27 from 25, with better delayed recall, and fewer headaches after months without alcohol. Neuropsychological testing is not needed now. **S**
   - Continue the headache and sleep plan; repeat MoCA in a year or sooner for any decline.
6. **Prediabetes** (R73.03). HbA1c 5.9% from 6.1%. Lipids improved without alcohol; estimated 10-year cardiovascular risk about 6%, so a statin is not recommended now. **S**
   - HbA1c and lipids yearly.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Hemoglobin before each phlebotomy (hold if under 12.0 g/dL) | Before every session; full blood count at visits | Completed today | Hemoglobin 13.4 g/dL, MCV 93 fL, platelets 226 |
| Laboratory | Serum ferritin during induction phlebotomy | At diagnosis, then about every 10 to 12 phlebotomies; target 50 to 100 ng/mL | Completed today | Ferritin 268 ng/mL after twenty-two sessions |
| Laboratory | Transferrin saturation | At diagnosis and as ferritin nears target | Completed today | Serum iron 148 ug/dL; transferrin saturation 44% |
| Medication safety | Weekly phlebotomy of 500 mL | Weekly during induction | Completed today | Twenty-two sessions; the twenty-third today |
| Imaging | Liver cancer surveillance | Every six months only with cirrhosis or advanced fibrosis | Not indicated | No advanced fibrosis |
| Imaging | Echocardiogram for iron-related heart disease | When symptoms or ECG changes, or with other cardiac indications | Completed today | Done today with the hypertension echocardiogram: no iron-related cardiomyopathy |
| Self-management | Diet: no iron or vitamin C supplements, no raw shellfish | Every visit | Completed today | No supplements; no raw shellfish |
| Laboratory | Liver tests on naltrexone | Baseline, about one month, then every three to six months | Completed today | AST 27, ALT 31 and GGT 41 U/L; normal |
| Survey | Drinking quantity and goal (AUDIT-C, drinking diary) | Every visit | Completed today | AUDIT-C 0; no alcohol for about fifteen weeks |
| Medication safety | Opioid use and pain plan on naltrexone | Every visit | Completed today | No opioids |
| Medication safety | Thiamine | While drinking or malnourished | Completed today | Stopped today |
| Survey | Depression (PHQ-9) | At least monthly during acute treatment | Completed today | PHQ-9 5, item 9 scored 0; monthly since the corrective action |
| Medication safety | Sertraline adherence and side effects | Two weeks after starting or changing the dose, then each visit | Completed today | 100 mg; no side effects |
| Survey | Suicide-risk review (C-SSRS screen since the last visit), safety plan, firearm storage and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | C-SSRS screen negative since the last visit; firearms remain off-site by his choice, with safe storage planned for their return |
| Self-management | Psychotherapy (CBT) | Weekly, then every two weeks | Completed today | Reduced to every two weeks |
| Examination | Blood pressure, home readings, weight and cardiac auscultation | Every visit | Completed today | 126/78 in clinic; home average 124/76; weight 92.8 kg; trace ankle edema |
| Imaging | Echocardiogram | At diagnosis of stage 2 hypertension | Completed today | Done this morning after the corrective action: mild concentric left ventricular hypertrophy, ejection fraction 60% |
| Laboratory | Lipid panel | Yearly | Completed today | Total cholesterol 194, LDL 114, HDL 49 and triglycerides 136 mg/dL |
| Laboratory | Urine albumin-to-creatinine ratio | Yearly | Up to date | 14 mg/g at intake |
| Laboratory | HbA1c | At diagnosis of prediabetes, then every six to twelve months | Completed today | HbA1c 5.9% |
| Survey | Cognitive screen (MoCA) | Baseline, then after three months with less or no alcohol | Completed today | MoCA 27 of 30, from 25; delayed recall improved |
| Examination | Post-concussion symptoms (headache frequency, sleep, concentration) | Every visit | Completed today | Headaches about once a week |
| Imaging | Brain imaging | Only for warning signs or decline | Not indicated | No warning signs; cognition improving |

## Goal progress

- Drinking goal chosen by him: no more than two drinks a day and none before evening, then reconsidered once the liver results are known. Outcome by 1955-06-08: Reduced to three or four drinks a day by six weeks; he then chose to stop, and has had no alcohol for three weeks. **S**
- Ferritin 50 to 100 ng/mL with weekly phlebotomy, then maintenance. Outcome by 1955-08-31: Ferritin 1,460 to 268 ng/mL after twenty-two sessions; induction continuing. **S**
- PHQ-9 below 5. Outcome by 1955-08-31: PHQ-9 16 to 5 at six months; response, nearly in remission. **S**
- Blood pressure below 130/80 mmHg. Outcome by 1955-08-31: 126/78 in clinic and an average of 124/76 at home on amlodipine 10 mg. **S**
- Fewer headaches and clearer thinking, so that he can write. Outcome by 1955-08-31: Headaches once a week from three; MoCA 25 to 27; writing every morning. **S**

## Medication changes

- Stopped: Thiamine 100 mg oral tablet, one tablet daily **S**

## Guideline basis

- Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases (2011), American Association for the Study of Liver Diseases (Hepatology 2011;54(1):328-343)
- ACG Clinical Guideline: Hereditary Hemochromatosis (2019), American College of Gastroenterology (Am J Gastroenterol 2019;114(8):1202-1218)
- The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018), American Psychiatric Association (Am J Psychiatry 2018;175(1):86-90)
- VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for the Management and Rehabilitation of Post-Acute Mild Traumatic Brain Injury (2021), United States Department of Veterans Affairs and Department of Defense
- Prediabetes and Type 2 Diabetes: Screening (2021), U.S. Preventive Services Task Force
- CMID: Clinical Monitoring Intelligence Database, hypertension and depression, bipolar, and mood disorders monographs (2026), Aether Forge

## Follow-up

- Weekly phlebotomy until ferritin is 50 to 100 ng/mL, then maintenance. Review in three months. Psychotherapy every two weeks and monthly PHQ-9. Colonoscopy as scheduled. **S**

